135 related articles for article (PubMed ID: 35577568)
41. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
[TBL] [Abstract][Full Text] [Related]
42. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.
Parisi M; Dogliotti I; Clerico M; Bertuzzo D; Benevolo G; Orsucci L; Schiavetti I; Cavallo R; Cavallo F; Ragaini S; Di Liberto A; Ferrante M; Bondielli G; Artusi CA; Drandi D; Lopiano L; Ferrero B; Ferrero S
Eur J Neurol; 2022 Dec; 29(12):3611-3622. PubMed ID: 36083713
[TBL] [Abstract][Full Text] [Related]
44. Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients.
Aotsuka Y; Misawa S; Suichi T; Shibuya K; Nakamura K; Kano H; Otani R; Morooka M; Ogushi M; Nagashima K; Sato Y; Kuriyama N; Kuwabara S
Eur J Neurol; 2024 May; 31(5):e16249. PubMed ID: 38375741
[TBL] [Abstract][Full Text] [Related]
45. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
46. Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy.
Massa F; Zuppa A; Pesce G; Demichelis C; Bergamaschi M; Garnero M; Briani C; Ferrari S; Schenone A; Benedetti L
J Neurol Sci; 2020 Jun; 413():116777. PubMed ID: 32200107
[TBL] [Abstract][Full Text] [Related]
47. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
48. Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy.
Doneddu PE; Kazmi M; Samuel M; Mahdi-Rogers M; Hadden RDM
J Neurol Sci; 2017 Feb; 373():344-345. PubMed ID: 28131219
[No Abstract] [Full Text] [Related]
49. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy.
Benedetti L; Franciotta D; Vigo T; Grandis M; Fiorina E; Ghiglione E; Roccatagliata L; Mancardi GL; Uccelli A; Schenone A
Arch Neurol; 2007 Oct; 64(10):1531-3. PubMed ID: 17923639
[TBL] [Abstract][Full Text] [Related]
50. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
51. Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.
Matà S; Ambrosini S; Saccomanno D; Biagioli T; Carpo M; Amantini A; Giannini F; Barilaro A; Toscani L; Del Mastio M; Comi GP; Sorbi S
Neurol Sci; 2020 Feb; 41(2):365-372. PubMed ID: 31654362
[TBL] [Abstract][Full Text] [Related]
52. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.
Gazzola S; Delmont E; Franques J; Boucraut J; Salort-Campana E; Verschueren A; Sagui E; Hubert AM; Pouget J; Attarian S
J Neurol Sci; 2017 Jun; 377():144-148. PubMed ID: 28477685
[TBL] [Abstract][Full Text] [Related]
53. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
[TBL] [Abstract][Full Text] [Related]
54. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
55. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
56. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody.
Mendell JR; Sahenk Z; Whitaker JN; Trapp BD; Yates AJ; Griggs RC; Quarles RH
Ann Neurol; 1985 Mar; 17(3):243-54. PubMed ID: 2581496
[TBL] [Abstract][Full Text] [Related]
57. Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies.
Delmont E; Attarian S; Antoine JC; Paul S; Camdessanché JP; Grapperon AM; Brodovich A; Boucraut J
J Neurol; 2019 Aug; 266(8):1973-1979. PubMed ID: 31089861
[TBL] [Abstract][Full Text] [Related]
58. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
59. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
[TBL] [Abstract][Full Text] [Related]
60. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody.
Rech J; Hueber AJ; Kallert S; Leipe J; Kalden JR; Beck M; Schett G; Schulze-Koops H
Ther Apher Dial; 2008 Jun; 12(3):205-8. PubMed ID: 18503697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
